5:02 PM
 | 
Feb 03, 2014
 |  BC Extra  |  Company News

EC approves Biogen Idec's Tecfidera

The European Commission approved an MAA from Biogen Idec Inc. (NASDAQ:BIIB) for Tecfidera dimethyl fumarate as first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The company said it plans to launch the product...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >